OH

Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage

Retrieved on: 
Thursday, November 9, 2023
Health policy, Policy, OH, MDD, TMS, STIM, Blue Cross Blue Shield Association, HI, Neuronetics, Major depressive disorder, DSM-IV codes, Psychotherapy, Criterion, OR, Quality of life, Marketing, Aetna, Transcranial magnetic stimulation, BCBS, SSM Health, CO, Patient, Regenerative Medicine Advanced Therapy, Pharmaceutical industry, Health insurance, Ferdinand Magellan, UnitedHealth Group, MD

Dean Health Plan has also removed the requirement for a prior trial of psychotherapy.

Key Points: 
  • Dean Health Plan has also removed the requirement for a prior trial of psychotherapy.
  • The policy updates from BCBS Kansas City and Dean Health Plan are effective immediately, with the Magellan update going into effect on November 18, 2023.
  • Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy changes.
  • For more information about NeuroStar TMS Therapy, please visit NeuroStar.com .

Schneider Electric and Compass Datacenters Expand Partnership with $3 Billion Multi-Year Data Center Technology Agreement

Retrieved on: 
Thursday, November 9, 2023
Capital market, Schneider Electric, Growth, OH, EV, Semiconductor, Automation, Cryptocurrency, Compass

The agreement extends the companies' existing relationship that integrates their respective supply chains to manufacture and deliver prefabricated modular data center solutions.

Key Points: 
  • The agreement extends the companies' existing relationship that integrates their respective supply chains to manufacture and deliver prefabricated modular data center solutions.
  • Since the inception of the initial agreement between the companies, Schneider Electric has manufactured and delivered about 150 modular data center solutions to Compass from its West Chester, OH operation.
  • "We are extremely grateful for the unwavering support and unparalleled expertise that Schneider Electric has already provided in supplying us with pre-fabricated data center power rooms," said Chris Crosby, CEO, Compass Datacenters.
  • "We are proud that Compass chose Schneider Electric as their data center partner because we can provide the infrastructure they require in a predictable and reliable manner," said Aamir Paul, President, Schneider Electric North America.

Unleashed Brands Honors Franchisees at Annual Conference

Retrieved on: 
Thursday, November 9, 2023
Urban Air, Education, OH, Leukemia, Chad, The Little Gym, Acquisition, NEXT Woman of the Year awards, GA, Atmosphere of Earth, Leukemia & Lymphoma Society, CO, United, Film industry, Toy

DALLAS, Nov. 9, 2023 /PRNewswire/ -- Unleashed Brands, the world's first youth enrichment franchise platform, recently recognized the achievements of more than two dozen franchisees across category-leading brands Urban Air Adventure Park, Snapology, The Little Gym, XP League, Class 101 and Premier Martial Arts at the company's annual franchisee conference in Hollywood, CA.

Key Points: 
  • DALLAS, Nov. 9, 2023 /PRNewswire/ -- Unleashed Brands , the world's first youth enrichment franchise platform, recently recognized the achievements of more than two dozen franchisees across category-leading brands Urban Air Adventure Park, Snapology , The Little Gym , XP League , Class 101 and Premier Martial Arts at the company's annual franchisee conference in Hollywood, CA.
  • The event connected franchisees from across the brands with more than 1,000 people in attendance.
  • The conference was centered on team building and workshops aimed to inspire and help franchisees grow their businesses.
  • The conference also marked the official debut of the Unleashed Brands Foundation , the charitable arm of Unleashed Brands committed to empowering at-risk youth and providing resources needed to successfully transition to adulthood through education, financial support and in-person volunteerism efforts.

Northern Tool + Equipment Opens First Retail Location in Ohio

Retrieved on: 
Thursday, November 9, 2023
OH, Partnership

SHARONVILLE, Ohio, Nov. 9, 2023 /PRNewswire/ -- Northern Tool + Equipment is excited to announce the opening of its newest location in Sharonville, OH. Customers are welcome to stop by the 2275 Crowne Point Dr. location starting November 15 and are encouraged to come back for a grand opening celebration taking place on December 9.

Key Points: 
  • SHARONVILLE, Ohio, Nov. 9, 2023 /PRNewswire/ -- Northern Tool + Equipment is excited to announce the opening of its newest location in Sharonville, OH.
  • "This is our first store serving Ohioans, and we're thrilled to join the community of Sharonville," said Northern Tool + Equipment VP of Retail Steve Spears.
  • The new location provides job opportunities to Sharonville and another retail shopping option for professional-grade tools at great prices.
  • "Sharonville is proud to become home to Northern Tool + Equipment's first Ohio store.

Lovell and MedRhythms Partner to Provide Access to InTandem™ for Veterans and Military Personnel with a Walking Impairment Due to a Stroke

Retrieved on: 
Wednesday, November 8, 2023
MHS, Stroke, Veterans Health Administration, IHS, OH, SDVOSB, FSS, Military personnel, Acquisition, GSA, Military Health System, Research, VHA, Quality of life, Rehabilitation, Lovell, Commercial, Partnership, Walking, RET, Indian Health Service, Patient, Pharmaceutical industry, Health insurance, Veteran

PORTLAND, Maine, Nov. 8, 2023 /PRNewswire/ -- Lovell Government Services and MedRhythms, Inc. announced their partnership establishing access to InTandem for Veterans and military personnel living with chronic stroke walking impairment. InTandem is a novel device that clinicians involved in stroke rehabilitation can prescribe to their patients to improve their walking and ambulation following a stroke.

Key Points: 
  • PORTLAND, Maine, Nov. 8, 2023 /PRNewswire/ -- Lovell Government Services and MedRhythms, Inc. announced their partnership establishing access to InTandem for Veterans and military personnel living with chronic stroke walking impairment.
  • InTandem is a novel device that clinicians involved in stroke rehabilitation can prescribe to their patients to improve their walking and ambulation following a stroke.
  • Over 80,000 Veterans have experienced at least one stroke .
  • Stroke is a leading cause of long-term disability including impairments to walking ability.

EXpressLO LLC Awarded U.S. Patent 11,808,679 for Cryo-EM Specimen Handling

Retrieved on: 
Tuesday, November 7, 2023
OH, Patent, Johns Hopkins, Microscopy and Microanalysis, Invention, MD, FIB, Research, Multimedia, APL, Bacteria, DOE, Applied Physics Laboratory, Microscopy, United States patent law, Microscope

LEHIGH ACRES, Fla., Nov. 7, 2023 /PRNewswire-PRWeb/ -- EXpressLO LLC was awarded U.S. Patent 11,808,679 from the U.S. Patent and Trademark Office describing highly innovative methods and apparatus for cryo-EXLO manipulation of biological and beam sensitive materials. EXpressLO LLC is the most comprehensive provider of focused ion beam (FIB) ex situ lift out (EXLO) specimen preparation solutions for transmission electron microscopy (EM) and other analytical techniques.

Key Points: 
  • EXpressLO LLC has been awarded U.S. Patent 11,808,679 from the USPTO for a unique cryogenic ex situ lift out specimen manipulation process for cryogenically prepared focused ion beam specimens.
  • LEHIGH ACRES, Fla., Nov. 7, 2023 /PRNewswire-PRWeb/ -- EXpressLO LLC was awarded U.S. Patent 11,808,679 from the U.S. Patent and Trademark Office describing highly innovative methods and apparatus for cryo-EXLO manipulation of biological and beam sensitive materials.
  • EXpressLO LLC is the most comprehensive provider of focused ion beam (FIB) ex situ lift out (EXLO) specimen preparation solutions for transmission electron microscopy (EM) and other analytical techniques.
  • The novel methods and apparatus described in this U.S. patent were invented by EXpressLO LLC founder and President, Dr. Lucille A. Giannuzzi.

Kasasa, Charlie Rocket, and Community Banks and Credit Unions Nationwide Exceed 300,000 Acts of Kindness During Best Day Ever Event

Retrieved on: 
Tuesday, November 7, 2023
Partner, Best, OH, Shoe, System, Food, Mercy Hospital, Dream, Closet, Wells Fargo, City, Dream Machine, Dream Factory, Community, Bank, Education

AUSTIN, Texas, Nov. 7, 2023 /PRNewswire/ -- Kasasa, which offers free reward checking accounts that have paid nearly $3 billion in rewards exclusively through community banks and credit unions, and Charlie Rocket's Dream Machine, partnered with hundreds of community banks and credit unions across the country to kick off the Best Day Ever event on November 3rd. The weekend culminated with a celebration at the Dream Factory hosted by Charlie Rocket and Gabe Krajicek, CEO of Kasasa.

Key Points: 
  • Community banks and credit unions across the country joined together to kick off the Best Day Ever event, which continued through the weekend from November 3-5.
  • With their outpouring of kindness and community action, the original goal of 100,000 acts of kindness was exceeded within the opening hours.
  • AUSTIN, Texas, Nov. 7, 2023 /PRNewswire/ -- Kasasa , which offers free reward checking accounts that have paid nearly $3 billion in rewards exclusively through community banks and credit unions, and Charlie Rocket's Dream Machine, partnered with hundreds of community banks and credit unions across the country to kick off the Best Day Ever event on November 3rd.
  • The Best Day Ever was a nationwide effort on behalf of Kasasa, Charlie Rocket, and hundreds of community banks and credit unions with the shared goal of reaching 100,000 acts of kindness in a single weekend.

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Retrieved on: 
Friday, November 3, 2023
CR, Neoplasm, Survival, WT1, MTD, DOI, H. Lee Moffitt Cancer Center & Research Institute, OH, Stomach, PDT, Ovarian cancer, EDT, Pembrolizumab, Nucleic acid thermodynamics, Infrared spectroscopy correlation table, DCR, MOS, HPV, Docetaxel, Chair, HNSCC, CPS, Phase, SITC, Cetuximab, Immunotherapy, SD, Clinical trial, Immune system, University Hospitals Cleveland Medical Center, Cancer, ORR, Blood, Methotrexate, EW, Society for Immunotherapy of Cancer, DSD, Safety, Society, Checkmate, Patient, DNA, UPR, Pharmaceutical industry, Vaccine, Communications satellite, Head, Lancet

New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.

Key Points: 
  • New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.
  • I look forward to evaluating the trial results as they continue to mature and remain highly encouraged by the observations to date.
  • Two patients at the 2mg/kg dose, one with gastric cancer and one with ovarian cancer have demonstrated reduction in tumor burden.
  • Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Retrieved on: 
Thursday, November 2, 2023
Trial of the century, OH, Event, Safety, Sickle cell disease, Society, ASH, Senior, American Society of Pediatric Hematology/Oncology, Caregiver, Fetal hemoglobin, Editas Medicine, Patient, Blood, Pharmaceutical industry, Nursing, Blood product, Edith A. Perez

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell disease and from the EdiTHAL trial of EDIT-301 in patients with transfusion-dependent beta thalassemia has been accepted for a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA, and online.

Key Points: 
  • Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m.
  • Editas Medicine will also host a Company-sponsored webinar on Monday, December 11, at 1:00 p.m.
  • ET to discuss the RUBY and EdiTHAL clinical data.
  • Clinical data on six patients, including at least five months data from the first two patients treated.

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Retrieved on: 
Wednesday, November 1, 2023
Blood vessel, Stroke, FDA, Carotid artery stenosis, OH, Incidence, OhioHealth, TEL, Mortality, NSPR, PMA, IDE, EPS, A. C. Guards, Clinical trial, Myocardial infarction, VIVA, Safety, Stent, Patient, Death, Medical device, Pharmaceutical industry, EU

The presentation, which was accepted as a late-breaking abstract, was delivered by Dr. Chris Metzger, System Vascular Chief at OhioHealth in Columbus, OH and principal investigator of the C-GUARDIANS trial.

Key Points: 
  • The presentation, which was accepted as a late-breaking abstract, was delivered by Dr. Chris Metzger, System Vascular Chief at OhioHealth in Columbus, OH and principal investigator of the C-GUARDIANS trial.
  • From July 2021 to June 2023, 316 patients were prospectively enrolled in this single-arm carotid artery stenting study performed at 24 sites in the US and the EU.
  • Stenting with the C-Guard carotid stent system in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a DSMI rate of 0.95%, from procedure through 30 days follow-up.
  • We believe the neuroprotective qualities of C-Guard set it apart from competing stents on the market and should help accelerate the ongoing shift in carotid revascularizations from ‘surgery first’ to an endovascular ‘stent first’ approach.